none alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: Control group, in addition to diet and exercise recommendations, use placebo capsules for 3 months. Intervention 2: Intervention group, in addition to diet and exercise recommendations
Placebo
Treatment - Drugs
Control group, in addition to diet and exercise recommendations, use placebo capsules for 3 months.
Intervention group, in addition to diet and exercise recommendations, use capsules containing fenugreek hydro alcoholic extract 1g / d for 3 months.
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: the level of ALT and AST greater than 1.5 and less than 10 times normal level; Ultrasound evidence confirm fatty liver disease; age between 18-70 years old; negative pregnancy test for women in reproductive age (up to two weeks prior to the study); negative for hepatitis B and C; BMI: 18.5 to 40; sign the consent form. Exclusion criteria: history of more than one unit of alcohol consumption (one value for the Spirits (vodka; whiskey); Wine and Beer are respectively 30-45 cc; 120-150 cc and 360 cc.); fatty liver controller medications; Glucose lowering drugs; Cholesterol lowering drugs; Hypotensive drugs; consumption of vitamin E; taking coenzyme Q10; administration of corticosteroids & glucocorticoids; thyroxin administration; administration of drugs that cause fatty liver; diabetes (type 1 and 2); history of cancer in the past; hepatocellular carcinoma; renal failure (creatinine> 1.5 x ULN); chronic pancreatitis; cirrhosis; uncontrolled hypertension (above 180 mm Hg systolic blood pressure); heart disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis (alkaline phosphatase levels greater than 3 times normal); Wilson's disease; alpha-1 antitrypsin deficiency and coronary artery disease; symptoms of hypothyroidism; hyperthyroidism; disorders of the hypothalamic – pituitary; liver transplantation; pregnant or lactating women; and those who cannot use contraceptives.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver stiffness. Timepoint: At baseline and 12 weeks after intervention. Method of measurement: Fibro scan.;Insulin resistance. Timepoint: At baseline and 6 and 12 weeks after intervention. Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAMir Hossein Babaei
Shiraz University of Medical Sciences
Outcome results
None listed